[
    [
        {
            "time": "",
            "original_text": "医药生物行业周报：新冠变异后是否需要常态化免疫加强？智飞新高后继续强烈看好",
            "features": {
                "keywords": [
                    "医药生物",
                    "新冠变异",
                    "常态化免疫",
                    "智飞",
                    "新高",
                    "强烈看好"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业周报：新冠变异后是否需要常态化免疫加强？智飞新高后继续强烈看好",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        }
    ]
]